Simulations Plus Integrates NVIDIA’s BioNeMo for AI-Driven Drug Development
Event summary
- Simulations Plus is building an agentic layer in its Composer platform using NVIDIA’s BioNeMo Agent Toolkit.
- The collaboration extends their May 2026 partnership to focus on GPU-accelerated simulation and AI-assisted modeling workflows.
- Initial efforts target scientific literature extraction via Nemotron™ Parse and accelerating quantitative systems pharmacology (QSP) with nvQSP.
The big picture
This collaboration aligns with the broader industry shift toward AI-driven drug discovery, where computational modeling and GPU acceleration are becoming critical for efficiency. Simulations Plus’ focus on maintaining scientific rigor while accelerating workflows positions it to capitalize on the growing demand for AI-assisted biopharma solutions.
What we're watching
- AI Adoption Pace
- How quickly Simulations Plus can integrate and commercialize agentic AI capabilities in drug development workflows.
- Competitive Differentiation
- Whether the NVIDIA collaboration will solidify Simulations Plus’ lead in model-informed drug development.
- Regulatory Compliance
- The impact of evolving AI regulations on the deployment and validation of agentic AI tools in biopharma.
Related topics